

Schrödinger, AstraZeneca join hands to accelerate drug discovery

05 September 2019 | News

Schrödinger's platform will be used by AstraZeneca's medicinal and computational chemists



Schrödinger, scientific leader in developing state-of-the-art chemical simulation software, has announced a collaboration with AstraZeneca to deploy Schrödinger's advanced computing platform to help accelerate drug discovery efforts.

Schrödinger's computational platform combines physics-based modeling and machine learning to enable chemists to predict the potency of a molecule binding to a target protein. This increases the likelihood that, when synthesized, compounds will have the correct properties required for further development and reduces the number of compounds that need to be synthesized.

Schrödinger's platform will be used by AstraZeneca's medicinal and computational chemists to help improve the design of compounds to identify potential new therapeutic candidates.

To ensure a comprehensive knowledge transfer, Schrödinger's team will work closely and share best practices with AstraZeneca to help integrate the platform into their drug discovery workflow.

Garry Pairaudeau, Global Chemistry Lead, R&D, AstraZeneca, commented: "Our strategic goal is to transform drug design using innovative digital technologies. In this collaboration with Schrödinger, we look forward to realizing the potential of predictive physics-based modeling and machine learning to help us deliver higher quality compounds more effectively."

"We are excited to launch this collaboration. AstraZeneca is a leader in embracing the potential of technology to reshape drug discovery, and we look forward to supporting them to deliver their vision for the future of drug design," said Schrödinger CEO Ramy Farid, Ph.D.